GentiBio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with an additional office in Seattle, Washington, developing engineered regulatory T cell (Treg) therapies to cure Type 1 diabetes and other autoimmune diseases.
Subscribe to see GentiBio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
GentiBio is a biotechnology company headquartered in Cambridge, United States, founded in 2020. Xcout tracks 20 named people at GentiBio, including Andy Walker (President and CEO).
As of 17 November 2026. Source: Xcout Intel.
14 more named people on record for GentiBio, with roles, board committees and tenure — see the full roster →
A few of GentiBio's closest competitors — see the full list of competitors and alternatives →
TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.
Oblenio Bio is a biotechnology research company headquartered in Lexington, Massachusetts, focused on transforming the treatment of refractory autoimmune diseases by delivering a broad immune system reset.
Egle Therapeutics SAS is a clinical-stage biotechnology company headquartered in Paris, France, that develops precision medicines designed to modulate regulatory T cells.
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about GentiBio? Suggest a correction · Work at GentiBio? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.